

Author Index for Volume 13

- ACAPS Group, 293
Ahn SA, 325
AIDS Clinical Trials Group (ACTG), 22
Allison MJ, 315
Anderson B, 91
Appel LJ, 240
- Bausell RB, 178
Bigger JT, Jr, 466
Birch R, 80, 156
Blackhurst DW, 40
Boichot HD, 325
Bond MG, 495
Bragg C, 156
Branyon M, 466
Bristol DR, 519
Brown MB, 213
Burchell HB, 185
Byar DP, 6
Byington RP, 495
- Caan B, 156
Campion J, 466
Cappelleri JC, 190
Carew BD, 325
Chalmers I, 100
CHF STAT Investigators, 339
Colling CL, 339
Conlon M, 134
Cooper E, 272
Corle DK, 6
Crouse JR, 495
Cutter GR, 80
- Davis KB, 226
de Pauw M, 351
Deedwania P, 339
Desu MM, 519
Dickersin K, 170, 507
Dierenfeldt BJ, 325
Dolan NA, 325
Dyer AR, 80
- Early Breast Cancer Trialists' Collaborative Group, 250
Edens TR, 325
Edler L, 517
Eigo J, 272
- Ellenberg SS, 272, 513
Espeland MA, 495
- Facey KM, 122
Feussner JR, 321
Finkelstein DM, 272, 513
Fisher S, 339
Fleiss JL, 466
Fletcher RD, 339
Freedman B, 1
Furberg CD, 495
- Gail MH, 6
Garcia-Lopez F, 507
Goldman AI, 256
Gorkin L, 466
Greenberg H, 93
- Hallstrom AP, 148
Handshaw K, 466
Hawkins BS, 40
Hertert S, 315
Hill AB, 515
Hill ID, 515
Hillman DW, 256
Hilner JE, 156
Hoth DF, 272
- Jones DR, 459
- Kahn JO, 513
Kershner RP, 248
Kinney MR, 466
- Lachin JM, 62
Lan S-P, 62
Lewis D, 339
Litwin PE, 148
Lui K-J, 446
Lupus Nephritis Collaborative Study Group, 62
- Machin D, 515
Marwaha S, 240
Massie B, 339
McBride R, 487
McDonald A, 156
McGovern M, 495
- Nusinoff-Lehrman S, 272
- Olschewski M, 226
Orr PR, 40
Ottenbacher K, 50
- Paridaens R, 250
Patel M, 240
Pechacek TF, 6
Perkins LL, 80
Probstfield JL, 325
- Raghavarao D, 519
Rennie D, 443
Reynolds-Haertle RA, 487
Rolnitzky LM, 466
Ryan TJ, 253
- Sacks H, 272
Savage PJ, 80
Schoenfelder J, 351
Schron E, 466
Schumacher M, 226
Shea S, 466
Silverman WA, 97, 100
Simel DL, 321
Singh B, 339
Singh S, 339
Slattery ML, 156
Smith JS, 181
Smoak CG, 156
Spilker B, 351
Sprinkle JW, 495
Studies of Ocular Complications of AIDS (SOCA) Research Group, 22
Sylvester R, 91, 178
- Thomas RG, 134
Trochim WMK, 190
- Van Horn L, 156
Vollmar J, 517
Vollmer WM, 315
- Wagenknecht LE, 80
Weaver WD, 148
Weiner DH, 325
Whelton PK, 240
Whitehead J, 106
Wittes J, 156

Subject Index for Volume 13

ACUTE MYOCARDIAL INFARCTION

- Thrombolytic Therapy for Acute Myocardial Infarction in the United States: We Started on the High Road, 253

ADVERSE DRUG REACTIONS

- The Future of Statistics and Statisticians in European Regulatory Affairs, 459

AIDS

- AIDS and the Ethics of Clinical Trials: Learning the Right Lessons, 1
- Studies of Ocular Complications of AIDS Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial: 1. Rationale, Design, and Methods, 22
- Studying Treatments for AIDS: New Challenges for Clinical Trials—A Panel Discussion at the 1990 Annual Meeting of the Society for Clinical Trials, 272

AMIODARONE

- Congestive Heart Failure: Survival Trial of Antiarrhythmic Therapy (CHF STAT), 339

ANTIARRHYTHMIC DRUG THERAPY

- Congestive Heart Failure: Survival Trial of Antiarrhythmic Therapy (CHF STAT), 339

ANTI-THROMBOTIC AGENTS

- Rationale and Design for the Asymptomatic Carotid Artery Plaque Study (ACAPS), 293

ASYMPTOTIC VARIANCE

- Sample Size Determination Under an Exponential Model in the Presence of a Confounder and Type I Censoring, 446

ATHEROSCLEROSIS

- Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries: Design Features of a Clinical Trial with Carotid Atherosclerosis Outcome, 495
- Rationale and Design for the Asymptomatic Carotid Artery

- Plaque Study (ACAPS), 293

BAYES ODDS RATIOS

- Termination of a Clinical Trial With No Treatment Group Difference: The Lupus Nephritis Collaborative Study, 62

BIAS

- Patient and Clinical Factors Predictive of Missed Visits and Inactive Status in a Multicenter Clinical Trial, 40

BLOOD PRESSURE MONITORING

- The Impact of Automated Blood Pressure Devices on the Efficiency of Clinical Trials, 240

BOOK REVIEWS

- Advanced Research Methodology: An Annotated Guide to Sources, by Bausell RB, 178
- Biometrie in der Chemisch-Pharmazeutischen Industrie 4. Stand und Perspektiven, ed. Volmar J, 517
- Data Collection Forms in Clinical Trials, by Spilker B, Schoenfelder J, 351
- Methodological Errors in Medical Research, by Andersen B, 91
- Methodological Issues in AIDS Clinical Trials, Volume 3, Supplement 2, 1990. Issue of *Journal of Acquired Immune Deficiency Syndromes*, eds. Ellenberg S, Kahn JO, 513
- Principles of Medical Statistics, 12th Ed., by Hill AB, Hill ID, 515
- Sample Size Methodology, by Desu MM, Raghavarao D, 519
- Treatment of Early Breast Cancer, Volume I. Worldwide Evidence 1985-1990, by Early Breast Cancer Trialists' Collaborative Group, 250

BRONCHIAL ASTHMA

- Recruiting Children and Their Families for Clinical Trials: A Case Study, 315

CARDIA

- Distributed Data Analysis in a Multicenter Study: The CARDIA Study, 80

Quality Control of Dietary Data Collection in the CARDIA Study, 156

CAROTID ATHEROSCLEROSIS

Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries: Design Features of a Clinical Trial with Carotid Atherosclerosis Outcome, 495

Rationale and Design for the Asymptomatic Carotid Artery Plaque Study (ACAPS), 293

CENSORING

A Method for Assigning Scores to the Components of a Composite Outcome: An Example from the MITI Trial, 148

CHILDREN

Recruiting Children and Their Families for Clinical Trials: A Case Study, 315

CHOLESTEROL

Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries: Design Features of a Clinical Trial with Carotid Atherosclerosis Outcome, 495

A Sequential Procedure for a Phase II Efficacy Trial in Hypercholesterolemia, 122

CLINICAL FACTORS

Patient and Clinical Factors Predictive of Missed Visits and Inactive Status in a Multicenter Clinical Trial, 40

CLINICAL TRIALS

Access to Data: A Contemporary Direction for Clinical Trials, 93

AIDS and the Ethics of Clinical Trials: Learning the Right Lessons, 1

Analysis of Randomized and Nonrandomized Patients in Clinical Trials Using the Comprehensive Cohort Follow-up Study Design, 226

Clinical Trials of Informed Consent, 321

Enrollment in Clinical Trial: Institutional Factors Affecting Enrollment in the Cardiac Arrhythmia Suppression Trial (CAST), 466

The Future of Statistics and Statisticians in European Regulatory Affairs, 459

The Impact of Automated Blood Pressure Devices on the Efficiency of Clinical Trials, 240

Overrunning and Underrunning in Sequential Clinical Trials, 106

Pravastatin, Lipids, and Atherosclerosis in

the Carotid Arteries: Design Features of a Clinical Trial with Carotid Atherosclerosis Outcome, 495

Recruiting Children and Their Families for Clinical Trials: A Case Study, 315

Regulatory Process Affects Clinical Trial Registration in Spain, 507

Studies of Ocular Complications of AIDS Foscarnet-Ganciclovir

Cytomegalovirus Retinitis Trial: 1.

Rationale, Design, and Methods, 22

Studying Treatments for AIDS: New Challenges for Clinical Trials—A Panel Discussion at the 1990 Annual Meeting of the Society for Clinical Trials, 272

Vicissitudes in Clinical Trial Research: Subjects, Participants, Patients, 185
Why Register Clinical Trials?—Revisited, 170

CLUSTER RANDOMIZATION

Aspects of Statistical Design for the Community Intervention Trial for Smoking Cessation (COMMIT), 6

COMMUNITY STUDIES

Aspects of Statistical Design for the Community Intervention Trial for Smoking Cessation (COMMIT), 6

COMPARATIVE TRIALS

The Impact of Automated Blood Pressure Devices on the Efficiency of Clinical Trials, 240

Sample Size Determination Based on Fisher's Exact Test for Use in 2 x 2 Comparative Trials with Low Event Rates, 134

COMPOSITE OUTCOME

A Method for Assigning Scores to the Components of a Composite Outcome: An Example from the MITI Trial, 148

COMPREHENSIVE COHORT FOLLOW-UP STUDY

Analysis of Randomized and Nonrandomized Patients in Clinical Trials Using the Comprehensive Cohort Follow-up Study Design, 226

CONDITIONAL POWER

Termination of a Clinical Trial With No Treatment Group Difference: The Lupus Nephritis Collaborative Study, 62

CONTROLLED CLINICAL TRIALS

Recruitment Strategies in the Studies of Left Ventricular Dysfunction (SOLVD): Strategies for Screening and Enrollment in Two Concurrent but Separate Trials, 325

COORDINATING CENTERS

Distributed Data Analysis in a Multicenter Study: The CARDIA Study, 80

COX'S PROPORTIONAL HAZARDS REGRESSION MODEL

Analysis of Randomized and Nonrandomized Patients in Clinical Trials Using the Comprehensive Cohort Follow-up Study Design, 226

CROSSOVER DESIGN

A Note on the Three-Period Two-Treatment Crossover Design (letter), 248

CUTOFF ASSIGNMENT STRATEGIES

Cutoff Assignment Strategies for Enhancing Randomized Clinical Trials, 190

CYTOMEGALOVIRUS RETINITIS

Studies of Ocular Complications of AIDS
Foscarnet-Ganciclovir
Cytomegalovirus Retinitis Trial:
1. Rationale, Design, and Methods, 22

DATA ACQUISITION

Access to Data: A Contemporary Direction for Clinical Trials, 93

Exemplary Data: Sample Size and Power in the Design of Event-Time Clinical Trials, 256

DATA ANALYSIS

Impact of Random Assignment on Study Outcome: An Empirical Examination, 50

DATA COLLECTION

Quality Control of Dietary Data Collection in the CARDIA Study, 156

DELAYED OBSERVATIONS

Overrunning and Underrunning in Sequential Clinical Trials, 106

DIETARY DATA COLLECTION

Quality Control of Dietary Data Collection in the CARDIA Study, 156

DISTRIBUTED DATA ANALYSIS

Distributed Data Analysis in a Multicenter Study: The CARDIA Study, 80

DOUBLE DATA ENTRY

Single vs. Double Data Entry in CAST, 487

DRUG REGULATION

The Future of Statistics and Statisticians in European Regulatory Affairs, 459

EDITORIALS

Access to Data: A Contemporary Direction for Clinical Trials, 93

ENROLLMENT

Enrollment in Clinical Trial: Institutional Factors Affecting Enrollment in the Cardiac Arrhythmia Suppression Trial (CAST), 466

ERROR RATES

Single vs. Double Data Entry in CAST, 487

ETHICS

AIDS and the Ethics of Clinical Trials:
Learning the Right Lessons, 1
Vicissitudes in Clinical Trial
Research: Subjects, Participants,
Patients, 185

EXTERNAL VALIDITY

Analysis of Randomized and Nonrandomized Patients in Clinical Trials Using the Comprehensive Cohort Follow-up Study Design, 226

FISHER'S EXACT TEST

Sample Size Determination Based on Fisher's Exact Test for Use in 2 x 2 Comparative Trials with Low Event Rates, 134

FOLLOW-UP

Patient and Clinical Factors Predictive of Missed Visits and Inactive Status in a Multicenter Clinical Trial, 40

FOSCARNET

Studies of Ocular Complications of AIDS
Foscarnet-Ganciclovir
Cytomegalovirus Retinitis Trial: 1.
Rationale, Design, and Methods, 22

FRANCIS, THOMAS, JR.

Remembering the Role of Thomas Francis, Jr. in the Design of the 1954 Salk Vaccine Trial, 181

GANCICLOVIR

Studies of Ocular Complications of AIDS
Foscarnet-Ganciclovir
Cytomegalovirus Retinitis Trial:
1. Rationale, Design, and Methods,
22

GROUP RANDOMIZATION

Aspects of Statistical Design for the
Community Intervention Trial for
Smoking Cessation (COMMIT), 6

HEART FAILURE, CONGESTIVE

Congestive Heart Failure: Survival Trial of
Antiarrhythmic Therapy (CHF
STAT), 339
Recruitment Strategies in the Studies of
Left Ventricular Dysfunction
(SOLVD): Strategies for Screening
and Enrollment in Two Concurrent
but Separate Trials, 325

HILL, AUSTIN BRADFORD (SIR)

Sir Austin Bradford Hill: An Appreciation,
100

HYPERCHOLESTEROLEMIA

A Sequential Procedure for a Phase II
Efficacy Trial in
Hypercholesterolemia, 122

HYPERTENSION

The Impact of Automated Blood Pressure
Devices on the Efficiency of Clinical
Trials, 240

IMPUTATION

A Test for the Difference Between Two
Treatments in a Continuous
Measure of Outcome When There
Are Dropouts, 213

INACTIVE STATUS

Patient and Clinical Factors Predictive of
Missed Visits and Inactive Status in
a Multicenter Clinical Trial, 40

INFORMED CONSENT

Clinical Trials of Informed Consent, 321

INTERPRETATION

Impact of Random Assignment on Study
Outcome: An Empirical
Examination, 50

INTIMA-MEDIA THICKNESS

Pravastatin, Lipids, and Atherosclerosis in
the Carotid Arteries: Design

Features of a Clinical Trial with
Carotid Atherosclerosis Outcome,
495

KEEPING POSTED

Regulatory Process Affects Clinical Trial
Registration in Spain, 507
Why Register Clinical Trials?—Revisited,
170

KEY DATA ENTRY

Single vs. Double Data Entry in CAST, 487

LDL CHOLESTEROL

Pravastatin, Lipids, and Atherosclerosis in
the Carotid Arteries: Design
Features of a Clinical Trial with
Carotid Atherosclerosis Outcome,
495

LETTERS TO THE EDITOR

A Note on the Three-Period Two-
Treatment Crossover Design, 248

LIKELIHOOD RATIOS

Termination of a Clinical Trial With No
Treatment Group Difference: The
Lupus Nephritis Collaborative
Study, 62

LIPID-LOWERING

Rationale and Design for the
Asymptomatic Carotid Artery
Plaque Study (ACAPS), 293

LONGRANK TEST

Exemplary Data: Sample Size and Power
in the Design of Event-Time Clinical
Trials, 256

MANN-WHITNEY TEST

A Test for the Difference Between Two
Treatments in a Continuous
Measure of Outcome When There
Are Dropouts, 213

MATCHING

Aspects of Statistical Design for the
Community Intervention Trial for
Smoking Cessation (COMMIT), 6

MEDICAL PRACTICE

Doctoring: From Art to Engineering, 97

MISSED VISITS

Patient and Clinical Factors Predictive of
Missed Visits and Inactive Status in
a Multicenter Clinical Trial, 40

MULTICENTER CLINICAL TRIALS

Distributed Data Analysis in a Multicenter Study: The CARDIA Study, 80
 Patient and Clinical Factors Predictive of Missed Visits and Inactive Status in a Multicenter Clinical Trial, 40

NONRESPONSE

A Test for the Difference Between Two Treatments in a Continuous Measure of Outcome When There Are Dropouts, 213

NONSTOCHASTIC DATA

Exemplary Data: Sample Size and Power in the Design of Event-Time Clinical Trials, 256

OBITUARY

Sir Austin Bradford Hill: An Appreciation, 100

OPHTHALMOLOGY

Studies of Ocular Complications of AIDS
 Foscarnet-Ganciclovir
 Cytomegalovirus Retinitis Trial:
 1. Rationale, Design, and Methods, 22

OVERRUNNING

Overrunning and Underrunning in Sequential Clinical Trials, 106

PARAMETERIZATION

A Sequential Procedure for a Phase II Efficacy Trial in Hypercholesterolemia, 122

PATIENT FACTORS

Patient and Clinical Factors Predictive of Missed Visits and Inactive Status in a Multicenter Clinical Trial, 40

PATIENT PARTICIPATION

Recruitment Strategies in the Studies of Left Ventricular Dysfunction (SOLVD): Strategies for Screening and Enrollment in Two Concurrent but Separate Trials, 325

PEER REVIEW

Editorial Peer Review: Let Us Put It On Trial, 443

PHASE II

A Sequential Procedure for a Phase II Efficacy Trial in Hypercholesterolemia, 122

PHI CORRELATION

Sample Size Determination Under an Exponential Model in the Presence of a Confounder and Type I Censoring, 446

PHYSICIAN'S ROLES

Doctoring: From Art to Engineering, 97

POWER

A Method for Assigning Scores to the Components of a Composite Outcome: An Example from the MITI Trial, 148
 Sample Size Determination Under an Exponential Model in the Presence of a Confounder and Type I Censoring, 446
 Termination of a Clinical Trial With No Treatment Group Difference: The Lupus Nephritis Collaborative Study, 62

QUALITY CONTROL

Quality Control of Dietary Data Collection in the CARDIA Study, 156

RANDOM ASSIGNMENT

Impact of Random Assignment on Study Outcome: An Empirical Examination, 50

RANDOMIZED CLINICAL TRIALS

Analysis of Randomized and Nonrandomized Patients in Clinical Trials Using the Comprehensive Cohort Follow-up Study Design, 226
 Cutoff Assignment Strategies for Enhancing Randomized Clinical Trials, 190
 Rationale and Design for the Asymptomatic Carotid Artery Plaque Study (ACAPS), 293

RANKING

A Method for Assigning Scores to the Components of a Composite Outcome: An Example from the MITI Trial, 148

RECRUITMENT

Recruiting Children and Their Families for Clinical Trials: A Case Study, 315

RECRUITMENT PERIOD

Sample Size Determination Under an Exponential Model in the Presence

of a Confounder and Type I
Censoring, 446

REDUCTASE INHIBITORS

Pravastatin, Lipids, and Atherosclerosis in
the Carotid Arteries: Design
Features of a Clinical Trial with
Carotid Atherosclerosis Outcome,
495

REGISTERS OF CLINICAL TRIALS

Why Register Clinical Trials?—Revisited,
170

REGISTRATION

Regulatory Process Affects Clinical Trial
Registration in Spain, 507

REGULATORY AFFAIRS

The Future of Statistics and Statisticians in
European Regulatory Affairs, 459
Regulatory Process Affects Clinical Trial
Registration in Spain, 507

RESEARCH DESIGN

Impact of Random Assignment on Study
Outcome: An Empirical
Examination, 50

RETINITIS

Studies of Ocular Complications of AIDS
Foscarnet-Ganciclovir
Cytomegalovirus Retinitis Trial: 1.
Rationale, Design, and Methods, 22

SALK VACCINE TRIAL

Remembering the Role of Thomas Francis,
Jr. in the Design of the 1954 Salk
Vaccine Trial, 181

SAMPLE SIZE

Sample Size Determination Based on
Fisher's Exact Test for Use in 2 x 2
Comparative Trials with Low Event
Rates, 134

Sample Size Determination Under
an Exponential Model in the
Presence of a Confounder and Type
I Censoring, 446

SCORING

A Method for Assigning Scores to the
Components of a Composite
Outcome: An Example from the
MITI Trial, 148

SEQUENTIAL ANALYSIS

Termination of a Clinical Trial With No

Treatment Group Difference: The
Lupus Nephritis Collaborative
Study, 62

SEQUENTIAL CLINICAL TRIALS

Overrunning and Underrunning in
Sequential Clinical Trials, 106
A Sequential Procedure for a Phase II
Efficacy Trial in
Hypercholesterolemia, 122

SMOKING PREVALENCE

Aspects of Statistical Design for
the Community Intervention
Trial for Smoking Cessation
(COMMIT), 6

SOCIETY FOR CLINICAL TRIALS

Annual Meetings, 1992-1996, 92
Fourteenth Annual Meeting of the Society
for Clinical Trials, 353
Officers—Board of Directors 1992-1993,
354
Studying Treatments for AIDS: New
Challenges for Clinical Trials—A
Panel Discussion at the 1990 Annual
Meeting of the Society for Clinical
Trials, 272
Thirteenth Annual Meeting of the Society
for Clinical Trials, 356

STOCHASTIC CURTAILING

Termination of a Clinical Trial With No
Treatment Group Difference: The
Lupus Nephritis Collaborative
Study, 62

STOPPING RULES

Overrunning and Underrunning in
Sequential Clinical Trials, 106

SUDDEN DEATH

Congestive Heart Failure: Survival Trial of
Antiarrhythmic Therapy (CHF
STAT), 339

SURVIVAL

Congestive Heart Failure: Survival Trial of
Antiarrhythmic Therapy (CHF
STAT), 339

SUSPENDED JUDGMENT

AIDS and the Ethics of Clinical Trials:
Learning the Right Lessons, 1
Clinical Trials of Informed Consent, 321
Doctoring: From Art to Engineering, 97
Editorial Peer Review: Let Us Put It On
Trial, 443

Remembering the Role of Thomas Francis, Jr. in the Design of the 1954 Salk Vaccine Trial, 181

Thrombolytic Therapy for Acute Myocardial Infarction in the United States: We Started on the High Road, 253

TERMINATION

Termination of a Clinical Trial With No Treatment Group Difference: The Lupus Nephritis Collaborative Study, 62

THROMBOLYTIC THERAPY

Thrombolytic Therapy for Acute Myocardial Infarction in the United States: We Started on the High Road, 253

TIMED EVENTS

Exemplary Data: Sample Size and Power in the Design of Event-Time Clinical Trials, 256

TRIANGULAR TEST

A Sequential Procedure for a Phase II Efficacy Trial in Hypercholesterolemia, 122

TWO-SAMPLE TEST

A Test for the Difference Between Two Treatments in a Continuous Measure of Outcome When There Are Dropouts, 213

ULTRASONOGRAPHY

Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries: Design Features of a Clinical Trial with Carotid Atherosclerosis Outcome, 495

Rationale and Design for the Asymptomatic Carotid Artery Plaque Study (ACAPS), 293

UNDERRUNNING

Overrunning and Underrunning in Sequential Clinical Trials, 106

VENTRICULAR ARRHYTHMIA

Congestive Heart Failure: Survival Trial of Antiarrhythmic Therapy (CHF STAT), 339

WITHDRAWALS

A Test for the Difference Between Two Treatments in a Continuous Measure of Outcome When There Are Dropouts, 213

